The Prohormone Scissor: How PCSK1 Variants Shape Insulin and Appetite
Every time your pancreas detects rising blood sugar, it doesn't release
insulin directly — it releases proinsulin, a folded precursor that needs
to be cut open before it becomes active. The enzyme doing that cutting
is prohormone convertase 1/3 (PC1/3)11 prohormone convertase 1/3 (PC1/3)
Encoded by the PCSK1 gene on
chromosome 5; cleaves inactive prohormone precursors at specific paired
basic amino acid sites to generate active peptide hormones, the protein encoded by
PCSK1. But PC1/3 doesn't work on proinsulin alone — it also cleaves
POMC into α-melanocyte-stimulating hormone (α-MSH), a key satiety
signal in the brain, and proglucagon into GLP-1, the incretin that
amplifies insulin release after meals. A single enzyme sits at the
convergence of insulin processing, appetite regulation, and incretin
signaling.
The rs10515237 variant sits within an intron of PCSK1 and is in [strong linkage disequilibrium | LD r² ≈ 0.84 in Europeans; variants that are tightly co-inherited — measuring one reliably predicts the other] with rs6234 and rs6235, the non-synonymous variants encoding the Q665E-S690T haplotype in the C-terminal domain of PC1/3. When you carry the G allele at rs10515237, you very likely also carry the functional haplotype that partially reduces PC1/3 activity. This is what makes rs10515237 clinically meaningful despite being intronic itself.
The Mechanism
The Q665E-S690T amino acid pair encoded by the rs6234-rs6235 haplotype
alters the C-terminal propeptide region of PC1/3. This region acts as
an intramolecular chaperone that guides proper protein folding — changes
to it reduce the enzyme's catalytic efficiency without abolishing function
entirely. The result is a partial loss-of-function22 partial loss-of-function
Not as severe as
the rare biallelic null mutations that cause severe early-onset obesity
and malabsorptive diarrhea; common heterozygous variants reduce activity
modestly that propagates
through three downstream pathways: slower proinsulin→insulin conversion
(raising the proinsulin-to-insulin ratio), reduced POMC cleavage to
α-MSH (blunting melanocortin-mediated satiety), and potentially altered
proglucagon processing to GLP-1 (modifying incretin responses).
The Evidence
The founding study, Benzinou et al. 2008 (Nature Genetics)33 Benzinou et al. 2008 (Nature Genetics)
13,659
individuals of European ancestry across 8 independent cohorts; the
Q665E-S690T haplotype was the strongest association signal at
p = 2.31 × 10⁻¹²,
established common PCSK1 variants as genuine obesity risk loci. The
rs6234-rs6235 haplotype — which rs10515237 tags — conferred a 22%
increased risk of obesity per risk haplotype in the original cohorts.
A companion functional experiment confirmed that the N221D mutation
(rs6232) significantly impaired PC1/3 catalytic activity in cell-based
assays.
The largest meta-analysis to date, Nead et al. 2015 (Human Molecular
Genetics)44 Nead et al. 2015 (Human Molecular
Genetics)
Up to 331,175 individuals from GWAS consortia; systematic
review combining literature and custom array data from diverse ethnic
backgrounds, quantified
the effect more precisely: the rs6234/rs6235 haplotype carries OR = 1.07
(95% CI 1.04–1.10, p = 3.00 × 10⁻⁷) for obesity, and rs6232 carries
OR = 1.15 (95% CI 1.06–1.24, p = 6.08 × 10⁻⁶). These are modest
effect sizes consistent with a polygenic contribution to a complex
trait. A HuGE review and meta-analysis by Stijnen et al. 201455 HuGE review and meta-analysis by Stijnen et al. 2014
Comprehensive systematic review of all published PCSK1 association studies;
examined associations with BMI, obesity, waist circumference confirmed the associations
and identified that rs6232 effects were stronger in childhood obesity
than adult obesity — consistent with the enzyme's role in early growth
and metabolic programming.
The metabolic consequence of reduced PC1/3 activity was directly
measured by Heni et al. 2010 (BMC Medical Genetics)66 Heni et al. 2010 (BMC Medical Genetics)
1,498 German
subjects with detailed OGTT and clamp studies; rs6235 minor allele
frequency 25.8%: carriers
of the rs6235 risk allele had 8% higher proinsulin area-under-the-curve
and elevated proinsulin-to-insulin ratio, confirming that the functional
haplotype measurably impairs prohormone processing in vivo.
Practical Implications
Carriers of the G allele at rs10515237 have a modestly elevated proinsulin-to-insulin ratio — their pancreatic beta cells are secreting more precursor and less active hormone per stimulus. Over time, this can translate into reduced beta-cell efficiency and elevated long-term diabetes risk. The satiety pathway impairment compounds this: if POMC-to-α-MSH conversion is reduced, the melanocortin-4 receptor pathway fires less robustly after meals, potentially raising the threshold at which fullness signals terminate eating. This combination — less effective insulin per secretory event plus blunted satiety — is the proposed mechanism linking PCSK1 variants to excess adiposity.
From a dietary standpoint, the primary lever is glycemic load. When meals generate rapid postprandial glucose peaks, beta cells secrete larger proinsulin pulses — and in PCSK1 G-allele carriers, those pulses are converted less efficiently. Spreading glucose load across the day by choosing lower-glycemic foods reduces the secretory burden on an already less-efficient processing system. Monitoring fasting proinsulin (where available) and the standard proinsulin:insulin ratio can detect beta-cell stress before HbA1c rises.
Interactions
The rs10515237/rs6234-rs6235 haplotype interacts additively with rs6232 (the N221D missense variant) within the same gene. Individuals carrying both the rs6232 risk allele and the rs6235 haplotype have two independently acting reductions in PC1/3 activity — compound heterozygosity within PCSK1 is plausible and would confer greater proinsulin accumulation. The melanocortin pathway interaction is also relevant: variants in MC4R (rs17782313) and POMC itself further modify satiety signaling downstream of PC1/3 cleavage, creating a polygenic appetite-regulation score that several GWAS consortia have begun characterizing.